Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Biotech Bestie Celgene Takes Stake, Inks $1 Billion+ Deal With BeiGene July 5, 2017 Amgen Faces Setback as Osteoporosis Drug is Linked to Serious Heart Side Effects May 21, 2017 InspireMD Announces Distribution Agreement For CGuard EPS In Taiwan June 7, 2017
